Alphastatin-Loaded Chitosan Nanoparticle Preparation and Its Antiangiogenic Effect on Lung Carcinoma

الملخص EN

Alphastatin is a 24-amino acid peptide and can suppress tumor angiogenesis by inhibiting both the migration and tubule formation of vascular endothelial cells.

However, the anticancer effect of Alphastatin is limited due to the short half-life and degradation in the body.

In this study, Alphastatin-loaded chitosan nanoparticles (AsCs NPs) were prepared with an initial concentration of 2 mg/ml for chitosan and 1 mg/ml for Alphastatin.

AsCs NPs presented the encapsulation efficiency of 32.4%, the mean particle size of 387.4 nm, the polydispersity index of 0.223, and the zeta potential of +28.1 mV.

AsCs NPs have a sustained release for 6 days and were stable in serum for at least 24 hours.

And the NPs could preserve the integrity of encapsulated Alphastatin and released Alphastatin for 24 hours.

In a subcutaneous LA975 lung carcinoma xenograft T739 mouse model, AsCs NPs significantly inhibited the tumor growth, tumor volume, and microvessel density (MVD), and the antitumor effect was even stronger than that of Alphastatin.

In addition, the VEGF-induced tube formation of HUVEC could be inhibited by AsCs NPs in vitro and the serum containing AsCs NPs, and the protein level of SphK1 in HUVEC was also decreased by AsCs NPs, suggesting an inhibitory effect of AsCs NPs on the SphK1-S1P signaling pathway.

Furthermore, hemolysis assay showed a safety on blood compatibility of AsCs NPs.

Our study indicated that AsCs NPs inhibited the SphK1-S1P signaling pathway and enhanced the antiangiogenic effect of Alphastatin both in vitro and in vivo.